Department of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China.
Institute of Medical Technology, Peking University Health Science Center, Beijing, 100191, China.
J Transl Med. 2023 Aug 4;21(1):526. doi: 10.1186/s12967-023-04386-y.
Primary liver cancer is one of the most common malignant tumours worldwide; it caused approximately 830,000 deaths in 2020. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for over 80% of all cases. Various methods, including surgery, chemotherapy, radiotherapy, and radiofrequency ablation, have been widely used in the treatment of HCC. With the advancement of technology, radiotherapy has become increasingly important in the comprehensive treatment of HCC. However, due to the insufficient sensitivity of tumour cells to radiation, there are still multiple limitation in clinical application of radiotherapy. In recent years, the role of immunotherapy in cancer has been increasingly revealed, and more researchers have turned their attention to the combined application of immunotherapy and radiotherapy in the hope of achieving better treatment outcomes. This article reviews the progress on radiation therapy in HCC and the current status of its combined application with immunotherapy, and discusses the prospects and value of radioimmunotherapy in HCC.
原发性肝癌是全球最常见的恶性肿瘤之一；2020 年约有 83 万人因此死亡。肝细胞癌（HCC）是最常见的原发性肝癌类型，占所有病例的 80%以上。手术、化疗、放疗和射频消融等各种方法已广泛应用于 HCC 的治疗。随着技术的进步，放疗在 HCC 的综合治疗中变得越来越重要。然而，由于肿瘤细胞对辐射的敏感性不足，放疗在临床应用中仍存在多种局限性。近年来，免疫疗法在癌症中的作用日益显现，更多的研究人员将注意力转向免疫疗法与放疗的联合应用，以期获得更好的治疗效果。本文综述了 HCC 的放射治疗进展及目前与免疫治疗联合应用的现状，并探讨了放射性免疫治疗在 HCC 中的应用前景和价值。
